RxDoctor Payments Data

Michelle Serig

Family · Tuscaloosa, ALNPI 1528538469

Payments from drug & device makers

$810in general payments, 2019–2025

Across 39 payments — averaging $20.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$199
  • Teva Pharmaceuticals USA, Inc.$173
  • AbbVie$134
  • Alkermes, Inc.$116
  • Lundbeck LLC$56
  • Merz Pharmaceuticals, LLC$42
  • plus $91 from 3 others

What the payments were for

  • Food & beverage$69986%
  • Education$11114%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$810 in reported general payments places this provider in the 60th percentile of 3,415 family providers in Alabama.

See all family providers in Alabama

Medicare billing

Part B allowed, 2024
$10,954
Medicare patients
90
Services billed
205

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate107$380,293
Abilify MaintenaAripiprazole56$149,027
Invega TrinzaPaliperidone Palmitate11$91,424
AustedoDeutetrabenazine18$87,928
IngrezzaValbenazine Tosylate12$84,760
AristadaAripiprazole Lauroxil18$64,095
RexultiBrexpiprazole23$32,776
VraylarCariprazine Hcl16$26,035
Paliperidone ErPaliperidone85$21,439
Lurasidone Hcl24$16,444
TrintellixVortioxetine Hydrobromide28$13,206
Aripiprazole104$7,862
Divalproex Sodium104$5,937
Olanzapine151$5,725
Quetiapine Fumarate245$4,232

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna, Invega Trinza$36$471,718118 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti$199$181,80379 claims
Teva Pharmaceuticals USA, Inc.Austedo$173$87,92818 claims
Alkermes, Inc.Aristada$116$64,09518 claims
AbbVieVraylar$134$26,03516 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 3,415 family providers in Alabama.

Other family in Tuscaloosa

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →